NRx Pharmaceuticals Inc. (NASDAQ:NRXP) finished Friday with a subtraction of -$0.02 to close at $0.32, a downside of -5.91 percent. An average of 5,798,860 shares of common stock have been traded in the last five days. There was a fall of -$0.0052 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 1,799,065 shares traded, while the 50-day average volume stands at 915,864.
NRXP stock has decreased by -8.96% in the last month. The company shares reached their 1-month lowest point of $0.2726 on 08/23/23. With the stock rallying to its 52-week high on 01/13/23, shares of the company touched a low of $0.27 and a high of $1.54 in 52 weeks. It has reached a new high 4 times so far this year and lost -71.18% or -$0.7901 in price. In spite of this, the price is down -79.23% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NRXP stock investors should be aware that NRx Pharmaceuticals Inc. (NRXP) stock had its last reported insider trading activity 262 days ago on Aug 23. In this transaction, the insider spent $400,000. 10% Owner, Javitt Daniel C., disposed of 8,441 shares at a price of $1.50 on Nov 30. The insider now owns more than $12,700 worth of shares. Prior to that, 10% Owner Javitt Daniel C. went on to Sale 13,730 shares at $1.50 each on Nov 29. An amount of $20,651 was transacted.
Valuation Metrics
NRx Pharmaceuticals Inc. (NRXP) stock’s beta is 0.84. Other valuation ratios to consider include the price-to-book (PB) ratio at 2.83.
Financial Health
The quick ratio of NRx Pharmaceuticals Inc. for the three months ended June 30 was 0.90, and the current ratio was 0.90, indicating that the company is not able to meet its debt obligations.
Earnings Surprise
The company posted a net income of -$8.72 million in the quarter, while revenues were grew 19.95%. The analyst consensus anticipated NRx Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.14 per share, but it turned out to be -$0.12, a 14.30% surprise. Shareholders own equity worth $81.7 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at NRx Pharmaceuticals Inc. (NRXP) price momentum. RSI 9-day as of the close on 25 August was 45.71%, suggesting the stock is Neutral, with historical volatility in this time frame at 115.15%.
As of today, NRXP’s price is $0.3126 -1.60% or -$0.0052 from its 5-day moving average. NRXP is currently trading -10.12% lower than its 20-day SMA and -48.60% lower than its 100-day SMA. However, the stock’s current price level is -40.91% below the SMA50 and -63.85% below the SMA200.
The stochastic %K and %D were 41.37% and 27.78%, respectively, and the average true range (ATR) was 0.0421. With the 14-day stochastic at 51.19% and the average true range at 0.0405, the RSI (14) stands at 42.69%. The stock has reached -0.0067 on the 9-day MACD Oscillator while the 14-day reading was at -0.0057.
Analyst Ratings
The consensus rating for NRx Pharmaceuticals Inc. (NRXP) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NRXP, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is NRXP’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $9.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for NRx Pharmaceuticals Inc. (NRXP) stock is $5.33.
